CN101821268B - 用于治疗丙型肝炎的四环化合物 - Google Patents
用于治疗丙型肝炎的四环化合物 Download PDFInfo
- Publication number
- CN101821268B CN101821268B CN200880110882XA CN200880110882A CN101821268B CN 101821268 B CN101821268 B CN 101821268B CN 200880110882X A CN200880110882X A CN 200880110882XA CN 200880110882 A CN200880110882 A CN 200880110882A CN 101821268 B CN101821268 B CN 101821268B
- Authority
- CN
- China
- Prior art keywords
- alkyl
- compound
- cyclohexyl
- methoxy
- indolo
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Fee Related
Links
- ZUQZJNCCUNCKLN-UHFFFAOYSA-N CC(C)(C)OC(c1ccc(c(C2CCCCC2)c-2[n]3CC(S(c4ccccc4)(=O)=O)=Cc4c-2ccc(OC)c4)c3c1)=O Chemical compound CC(C)(C)OC(c1ccc(c(C2CCCCC2)c-2[n]3CC(S(c4ccccc4)(=O)=O)=Cc4c-2ccc(OC)c4)c3c1)=O ZUQZJNCCUNCKLN-UHFFFAOYSA-N 0.000 description 1
- NADGBGVJILMKBO-UHFFFAOYSA-N CC(C)(C)OC(c1ccc(c(C2CCCCC2)c-2[n]3CC(c(nccc4)c4C(N4CCOCC4)=O)=Cc4c-2ccc(OC)c4)c3c1)=O Chemical compound CC(C)(C)OC(c1ccc(c(C2CCCCC2)c-2[n]3CC(c(nccc4)c4C(N4CCOCC4)=O)=Cc4c-2ccc(OC)c4)c3c1)=O NADGBGVJILMKBO-UHFFFAOYSA-N 0.000 description 1
- ZFZHJKBVAURSTF-UHFFFAOYSA-N CC(C)S(NC(c(cc1)cc2c1c(C1CCCCC1)c-1[n]2CC(c(cccc2)c2S(N(C)C)(=O)=O)=Cc2c-1ccc(OC)c2)=O)(=O)=O Chemical compound CC(C)S(NC(c(cc1)cc2c1c(C1CCCCC1)c-1[n]2CC(c(cccc2)c2S(N(C)C)(=O)=O)=Cc2c-1ccc(OC)c2)=O)(=O)=O ZFZHJKBVAURSTF-UHFFFAOYSA-N 0.000 description 1
- XYCRSBFKYXMXGB-UHFFFAOYSA-N CC(C)S(NC(c1ccc(c(C2CCCCC2)c(-c(cc2)c(C3)cc2OC)[n]2CC3c3cc(OCCN(C)C)ccn3)c2c1)=O)(=O)=O Chemical compound CC(C)S(NC(c1ccc(c(C2CCCCC2)c(-c(cc2)c(C3)cc2OC)[n]2CC3c3cc(OCCN(C)C)ccn3)c2c1)=O)(=O)=O XYCRSBFKYXMXGB-UHFFFAOYSA-N 0.000 description 1
- 0 CCC(*)C(c(c(*1CC(c(cccc2)c2C(OC)=O)=Cc2c3)c4)ccc4C(*)=O)=C1c2ccc3OC Chemical compound CCC(*)C(c(c(*1CC(c(cccc2)c2C(OC)=O)=Cc2c3)c4)ccc4C(*)=O)=C1c2ccc3OC 0.000 description 1
- KKIPXMHIOAXGRQ-UHFFFAOYSA-N CCC(CC)c1c(-c(ccc(OC)c2)c2C=C(C2)c(cc(C(F)(F)F)cc3)c3N3CCOCC3)[n]2c2cc(C(NS(C(C)C)(=O)=O)=O)ccc12 Chemical compound CCC(CC)c1c(-c(ccc(OC)c2)c2C=C(C2)c(cc(C(F)(F)F)cc3)c3N3CCOCC3)[n]2c2cc(C(NS(C(C)C)(=O)=O)=O)ccc12 KKIPXMHIOAXGRQ-UHFFFAOYSA-N 0.000 description 1
- ORZMHAMJGKEYIK-UHFFFAOYSA-N O=S(c(cccn1)c1Cl)N1CCOCC1 Chemical compound O=S(c(cccn1)c1Cl)N1CCOCC1 ORZMHAMJGKEYIK-UHFFFAOYSA-N 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/04—Ortho-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D519/00—Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups C07D453/00 or C07D455/00
Landscapes
- Organic Chemistry (AREA)
- Chemical & Material Sciences (AREA)
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Chemical & Material Sciences (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Communicable Diseases (AREA)
- Oncology (AREA)
- Virology (AREA)
- Molecular Biology (AREA)
- Gastroenterology & Hepatology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US95481307P | 2007-08-09 | 2007-08-09 | |
| US60/954,813 | 2007-08-09 | ||
| PCT/US2008/072295 WO2009023487A1 (en) | 2007-08-09 | 2008-08-06 | Tetracyclic compounds for the treatment of hepatitis c |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CN101821268A CN101821268A (zh) | 2010-09-01 |
| CN101821268B true CN101821268B (zh) | 2013-01-30 |
Family
ID=40002880
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN200880110882XA Expired - Fee Related CN101821268B (zh) | 2007-08-09 | 2008-08-06 | 用于治疗丙型肝炎的四环化合物 |
Country Status (7)
| Country | Link |
|---|---|
| US (1) | US7642251B2 (enExample) |
| EP (1) | EP2178878B1 (enExample) |
| JP (1) | JP5406837B2 (enExample) |
| CN (1) | CN101821268B (enExample) |
| AT (1) | ATE551343T1 (enExample) |
| ES (1) | ES2383247T3 (enExample) |
| WO (1) | WO2009023487A1 (enExample) |
Families Citing this family (15)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP1688420A4 (en) * | 2003-11-19 | 2008-10-22 | Japan Tobacco Inc | 5-5 LOW-CONDENSED HETEROCYCLIC COMPOUND AND THEIR USE AS HCV POLYMERASE INHIBITOR |
| US20070049593A1 (en) * | 2004-02-24 | 2007-03-01 | Japan Tobacco Inc. | Tetracyclic fused heterocyclic compound and use thereof as HCV polymerase inhibitor |
| US7659263B2 (en) | 2004-11-12 | 2010-02-09 | Japan Tobacco Inc. | Thienopyrrole compound and use thereof as HCV polymerase inhibitor |
| US8143243B2 (en) * | 2007-08-09 | 2012-03-27 | Bristol-Myers Squibb Company | Compounds for the treatment of hepatitis C |
| PL2209789T3 (pl) * | 2007-11-20 | 2012-04-30 | Bristol Myers Squibb Co | Skondensowane z cyklopropylem indolobenzoazepinowe inhibitory NS5B HCV |
| US8129367B2 (en) * | 2007-11-21 | 2012-03-06 | Bristol-Myers Squibb Company | Compounds for the treatment of Hepatitis C |
| JP2011517673A (ja) | 2008-03-27 | 2011-06-16 | ブリストル−マイヤーズ スクイブ カンパニー | 芳香族ヘテロ環縮合インドロベンザジアゼピンｈｃｖｎｓ５ｂ阻害剤 |
| US8133884B2 (en) * | 2008-05-06 | 2012-03-13 | Bristol-Myers Squibb Company | Compounds for the treatment of hepatitis C |
| US8143244B2 (en) * | 2009-02-26 | 2012-03-27 | Bristol-Myers Squibb Company | Cyclopropyl fused indolobenzazepine HCV NS5B inhibitors |
| JP5913091B2 (ja) | 2009-03-27 | 2016-04-27 | メルク・シャープ・アンド・ドーム・コーポレーションＭｅｒｃｋ Ｓｈａｒｐ ＆ Ｄｏｈｍｅ Ｃｏｒｐ． | Ｃ型肝炎ウイルス複製の阻害剤 |
| US20190127365A1 (en) | 2017-11-01 | 2019-05-02 | Merck Sharp & Dohme Corp. | Inhibitors of hepatitis c virus replication |
| JP2013540122A (ja) | 2010-09-29 | 2013-10-31 | メルク・シャープ・エンド・ドーム・コーポレイション | 縮合四環式化合物誘導体およびウィルス疾患治療のためのそれの使用方法 |
| WO2012122716A1 (en) | 2011-03-17 | 2012-09-20 | Merck Sharp & Dohme Corp. | Tetracyclic xanthene derivatives and methods of use thereof for treatment of viral diseases |
| WO2014110687A1 (en) | 2013-01-16 | 2014-07-24 | Merck Sharp & Dohme Corp. | Thiazolyl-substitued tetracyclic compounds and methods of use thereof for treatment of viral diseases |
| CN105440048A (zh) * | 2014-09-28 | 2016-03-30 | 复旦大学 | 1,3-苯并二噁茂类化合物山芝麻素及其药物用途 |
Family Cites Families (20)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DE602005013922D1 (de) | 2004-02-24 | 2009-05-28 | Japan Tobacco Inc | Kondensierte heterotetracyclische verbindungen und deren verwendung als hcv-polymerase-inhibitor |
| US7153848B2 (en) | 2004-08-09 | 2006-12-26 | Bristol-Myers Squibb Company | Inhibitors of HCV replication |
| AU2005298403A1 (en) | 2004-10-26 | 2006-05-04 | Istituto Di Ricerche Di Biologia Molecolare P Angeletti Spa | Tetracyclic indole derivatives as antiviral agents |
| GB0518390D0 (en) | 2005-09-09 | 2005-10-19 | Angeletti P Ist Richerche Bio | Therapeutic compounds |
| US7399758B2 (en) * | 2005-09-12 | 2008-07-15 | Meanwell Nicholas A | Cyclopropyl fused indolobenzazepine HCV NS5B inhibitors |
| US7473688B2 (en) * | 2005-09-13 | 2009-01-06 | Bristol-Myers Squibb Company | Indolobenzazepine HCV NS5B inhibitors |
| US7456165B2 (en) * | 2006-02-08 | 2008-11-25 | Bristol-Myers Squibb Company | HCV NS5B inhibitors |
| GB0608928D0 (en) | 2006-05-08 | 2006-06-14 | Angeletti P Ist Richerche Bio | Therapeutic agents |
| US7456166B2 (en) * | 2006-05-17 | 2008-11-25 | Bristol-Myers Squibb Company | Cyclopropyl fused indolobenzazepine HCV NS5B inhibitors |
| US7521441B2 (en) * | 2006-05-22 | 2009-04-21 | Bristol-Myers Squibb Company | Cyclopropyl fused indolobenzazepine HCV NS5B inhibitors |
| US7521442B2 (en) * | 2006-05-25 | 2009-04-21 | Bristol-Myers Squibb Company | Cyclopropyl fused indolobenzazepine HCV NS5B inhibitors |
| CN101490054B (zh) * | 2006-05-25 | 2012-05-16 | 百时美施贵宝公司 | 环丙基稠合的吲哚并苯并氮杂*hcv ns5b抑制剂 |
| US7452876B2 (en) * | 2006-06-08 | 2008-11-18 | Bristol-Myers Squibb Company | Cyclopropyl fused indolobenzazepine HCV NS5B inhibitors |
| US7541351B2 (en) * | 2007-01-11 | 2009-06-02 | Bristol-Myers Squibb Company | Compounds for the treatment of hepatitis C |
| US7517872B2 (en) * | 2007-02-22 | 2009-04-14 | Bristol-Myers Squibb Company | Compounds for the treatment of hepatitis C |
| US7541353B2 (en) * | 2007-03-14 | 2009-06-02 | Bristol-Myers Squibb Company | Compounds for the treatment of hepatitis C |
| US7547690B2 (en) * | 2007-03-14 | 2009-06-16 | Bristol-Myers Squibb Company | Compounds for the treatment of Hepatitis C |
| US7521444B2 (en) * | 2007-03-14 | 2009-04-21 | Bristol-Myers Squibb Company | Compounds for the treatment of hepatitis C |
| US7538102B2 (en) * | 2007-03-14 | 2009-05-26 | Bristol-Myers Squibb Company | Compounds for the treatment of Hepatitis C |
| US7538103B2 (en) * | 2007-03-15 | 2009-05-26 | Bristol-Myers Squibb Company | Compounds for the treatment of hepatitis C |
-
2008
- 2008-08-01 US US12/184,791 patent/US7642251B2/en active Active
- 2008-08-06 WO PCT/US2008/072295 patent/WO2009023487A1/en not_active Ceased
- 2008-08-06 AT AT08797248T patent/ATE551343T1/de active
- 2008-08-06 CN CN200880110882XA patent/CN101821268B/zh not_active Expired - Fee Related
- 2008-08-06 JP JP2010520272A patent/JP5406837B2/ja not_active Expired - Fee Related
- 2008-08-06 ES ES08797248T patent/ES2383247T3/es active Active
- 2008-08-06 EP EP08797248A patent/EP2178878B1/en not_active Not-in-force
Non-Patent Citations (1)
| Title |
|---|
| Kazutaka Ikegashira, et al..Discovery of Conformationally Constrained Tetracyclic Compounds as Potent Hepatitis C Virus NS5B RNA Polymerase Inhibitors.《J. Med. Chem.》.2006,第49卷(第24期),第6950-6953页. * |
Also Published As
| Publication number | Publication date |
|---|---|
| US20090042860A1 (en) | 2009-02-12 |
| WO2009023487A1 (en) | 2009-02-19 |
| EP2178878B1 (en) | 2012-03-28 |
| US7642251B2 (en) | 2010-01-05 |
| CN101821268A (zh) | 2010-09-01 |
| EP2178878A1 (en) | 2010-04-28 |
| JP2010535799A (ja) | 2010-11-25 |
| JP5406837B2 (ja) | 2014-02-05 |
| ATE551343T1 (de) | 2012-04-15 |
| ES2383247T3 (es) | 2012-06-19 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN101821268B (zh) | 用于治疗丙型肝炎的四环化合物 | |
| AU2007211988B2 (en) | HCV NS5B inhibitors | |
| CN101490054B (zh) | 环丙基稠合的吲哚并苯并氮杂*hcv ns5b抑制剂 | |
| CN101631790B (zh) | 用于治疗丙型肝炎的化合物 | |
| CN101730698B (zh) | 用于治疗丙型肝炎的化合物 | |
| US7521442B2 (en) | Cyclopropyl fused indolobenzazepine HCV NS5B inhibitors | |
| EP2118109B1 (en) | Compounds for the treatment of hepatitis c | |
| EP2118110B1 (en) | Cyclopropyl fused indolobenzazepine hcv inhibitors | |
| CN101679441B (zh) | 用于治疗丙型肝炎的化合物 | |
| CN101918410B (zh) | 与环丙基稠合的吲哚并苯并氮杂*hcv ns5b抑制剂 | |
| CN101679442B (zh) | 用于治疗丙型肝炎的化合物 | |
| CN101918412B (zh) | 用于治疗丙型肝炎的稠合有环丙基的吲哚并苯并氮杂*衍生物 | |
| US7998951B2 (en) | HCV NS5B inhibitors | |
| CN101821267B (zh) | 用于治疗丙型肝炎的化合物 | |
| EP2401280B1 (en) | Cyclopropyl fused indolobenzazepine hcv ns5b inhibitors | |
| CN101646674B (zh) | 用于治疗丙型肝炎的吲哚并苯并氮杂*衍生物 | |
| AU2009228337A1 (en) | Compounds for the treatment of hepatitis C | |
| CN101443336B (zh) | 环丙基稠合的[吲哚]并[苯并氮杂*]hcv ns5b抑制剂 |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| C06 | Publication | ||
| PB01 | Publication | ||
| C10 | Entry into substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| C14 | Grant of patent or utility model | ||
| GR01 | Patent grant | ||
| CF01 | Termination of patent right due to non-payment of annual fee |
Granted publication date: 20130130 Termination date: 20150806 |
|
| EXPY | Termination of patent right or utility model |